ATE204468T1 - Mittel zur verzögerten freisetzung von menschlichem wachstumshormon - Google Patents
Mittel zur verzögerten freisetzung von menschlichem wachstumshormonInfo
- Publication number
- ATE204468T1 ATE204468T1 AT96919016T AT96919016T ATE204468T1 AT E204468 T1 ATE204468 T1 AT E204468T1 AT 96919016 T AT96919016 T AT 96919016T AT 96919016 T AT96919016 T AT 96919016T AT E204468 T1 ATE204468 T1 AT E204468T1
- Authority
- AT
- Austria
- Prior art keywords
- composition
- hgh
- biologically active
- sustained release
- polymer
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 9
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 9
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 9
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000003111 delayed effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 6
- 238000013268 sustained release Methods 0.000 abstract 6
- 239000012730 sustained-release form Substances 0.000 abstract 6
- 239000002245 particle Substances 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 4
- 229920000249 biocompatible polymer Polymers 0.000 abstract 3
- 230000036765 blood level Effects 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 230000002459 sustained effect Effects 0.000 abstract 2
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/477,725 US5667808A (en) | 1992-12-02 | 1995-06-07 | Composition for sustained release of human growth hormone |
US08/473,544 US5654010A (en) | 1992-12-02 | 1995-06-07 | Composition for sustained release of human growth hormone |
PCT/US1996/008086 WO1996040072A2 (en) | 1995-06-07 | 1996-06-03 | Composition for sustained release of human growth hormone |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE204468T1 true ATE204468T1 (de) | 2001-09-15 |
Family
ID=27044171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96919016T ATE204468T1 (de) | 1995-06-07 | 1996-06-03 | Mittel zur verzögerten freisetzung von menschlichem wachstumshormon |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0831787B1 (de) |
JP (1) | JPH11506740A (de) |
CN (1) | CN1102854C (de) |
AT (1) | ATE204468T1 (de) |
AU (1) | AU708756B2 (de) |
BR (1) | BR9608542A (de) |
CA (1) | CA2223436A1 (de) |
CZ (1) | CZ288147B6 (de) |
DE (1) | DE69614685T2 (de) |
DK (1) | DK0831787T3 (de) |
ES (1) | ES2161366T3 (de) |
HK (1) | HK1009089A1 (de) |
HU (1) | HUP9900870A3 (de) |
IL (1) | IL122385A (de) |
MX (1) | MX9709698A (de) |
NO (1) | NO316104B1 (de) |
NZ (1) | NZ310644A (de) |
PL (1) | PL184531B1 (de) |
PT (1) | PT831787E (de) |
RU (1) | RU2161502C2 (de) |
SK (1) | SK281571B6 (de) |
WO (1) | WO1996040072A2 (de) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997001331A2 (en) * | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
WO1998027980A2 (en) * | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
US6663899B2 (en) | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6191107B1 (en) * | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
NZ525914A (en) | 1998-03-10 | 2004-03-26 | Genentech Inc | Novel polypeptides and nucleic acids encoding the same |
EP3112468A1 (de) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17-homologe polypeptide und therapeutische verwendung davon |
EP1076703B2 (de) | 1998-05-15 | 2010-12-15 | Genentech, Inc. | Therapeutische verwendungen von il-17 homologe polypeptide |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
DE60043367D1 (de) | 1999-06-15 | 2009-12-31 | Genentech Inc | Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung |
CA2391455A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
DK1897945T3 (da) | 1999-12-23 | 2012-05-07 | Genentech Inc | IL-17 homologe polypeptider og terapeutiske anvendelser deraf. |
CN1425066B (zh) | 2000-01-13 | 2010-05-26 | 杰南技术公司 | 新的stra6多肽 |
US6740520B2 (en) | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
EP1265630B1 (de) | 2000-03-24 | 2006-06-07 | Genentech, Inc. | Verwendung von insulin zur behandlung von knorpelkrankheiten |
US6998137B2 (en) * | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
ATE412009T1 (de) | 2000-08-24 | 2008-11-15 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
EP1944317A3 (de) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US8637077B2 (en) | 2000-12-28 | 2014-01-28 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
WO2002092619A2 (en) | 2001-05-14 | 2002-11-21 | The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified growth hormone |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
JP4460892B2 (ja) | 2001-06-21 | 2010-05-12 | ジェネンテック インコーポレイテッド | 徐放性組成物 |
JP2005518212A (ja) | 2002-02-25 | 2005-06-23 | ジェネンテック・インコーポレーテッド | 新規な1型サイトカインレセプターglm−r |
CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
PT1636593E (pt) | 2003-06-06 | 2009-06-03 | Genentech Inc | Modulação da interacção entre a cadeia beta de hgf e c-met |
ES2424353T3 (es) | 2003-07-08 | 2013-10-01 | Genentech, Inc. | Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos |
EP1692178A1 (de) | 2003-12-11 | 2006-08-23 | Genentech, Inc. | Verfahren und produkt um c-met dimerisierung und aktivierung zu verhindern |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
JP5010464B2 (ja) | 2004-03-30 | 2012-08-29 | エヌエスジーン・アクティーゼルスカブ | 成長因子、NsG33の治療上の使用 |
EP1814574A4 (de) | 2004-10-27 | 2009-08-05 | Univ Denver | Analoga des adrenocorticotropen hormons und entsprechende verfahren |
EP1827401A2 (de) | 2004-12-10 | 2007-09-05 | Talima Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von leiden der nägel |
US20060275230A1 (en) | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
US8389469B2 (en) | 2005-06-06 | 2013-03-05 | The Rockefeller University | Bacteriophage lysins for Bacillus anthracis |
JP2008541781A (ja) | 2005-06-06 | 2008-11-27 | ジェネンテック・インコーポレーテッド | 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用 |
SI1899378T1 (sl) | 2005-06-21 | 2010-02-26 | Xoma Technology Ltd | IL-1Beta vezavna protitelesa in njihovi fragmenti |
US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
ZA200800970B (en) | 2005-08-15 | 2009-10-28 | Genentech Inc | Gene disruptions, compositions and methods relating thereto |
WO2007024628A2 (en) | 2005-08-24 | 2007-03-01 | The Rockefeller University | Ply-gbs mutant lysins |
ZA200804162B (en) | 2005-11-21 | 2009-12-30 | Genentech Inc | Novel gene disruptions, compositions and methods relating thereto |
US20080032343A1 (en) | 2005-12-22 | 2008-02-07 | Genentech, Inc. | Recombinant Production of Heparin Binding Proteins |
ZA200807714B (en) | 2006-02-17 | 2010-01-27 | Genentech Inc | Gene disruptions, compositions and methods relating thereto |
EP2004221A2 (de) | 2006-03-23 | 2008-12-24 | Novartis Pharma AG | Antitumorzellenantigen-antikörper-therapeutika |
US7695928B2 (en) | 2006-04-10 | 2010-04-13 | Genentech, Inc. | Disheveled PDZ modulators |
CA2649387A1 (en) | 2006-04-19 | 2008-03-27 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
KR101524880B1 (ko) * | 2006-08-31 | 2015-06-01 | 노파르티스 아게 | Hgh를 포함하는 경구 전달용 제약 조성물 |
EP3124045A3 (de) | 2006-12-20 | 2017-05-03 | Xoma (Us) Llc | Behandlung von il-1-beta-bedingten erkrankungen |
CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
EP2185701A4 (de) * | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | Zusammensetzungen und verfahren zur veränderung von eigenschaften biologisch aktiver polypeptide |
MX2010006823A (es) | 2007-12-20 | 2010-09-30 | Xoma Technology Ltd | Metodos para el tratamiento de la gota. |
GB0812742D0 (en) | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
MX368790B (es) | 2009-10-15 | 2019-10-16 | Genentech Inc | Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada. |
WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
JP5878477B2 (ja) | 2010-01-15 | 2016-03-08 | ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー | 骨の治癒を加速するためのバナジウム化合物の使用 |
SI2550018T1 (sl) | 2010-03-22 | 2019-05-31 | F. Hoffmann-La Roche Ag | Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine |
MX2012012743A (es) | 2010-05-03 | 2012-11-23 | Genentech Inc | Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina. |
AU2011270828B2 (en) | 2010-06-24 | 2015-09-24 | Genentech, Inc. | Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations |
CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
CA2813013C (en) | 2010-10-01 | 2019-10-22 | Nsgene A/S | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
US9345765B2 (en) | 2010-10-08 | 2016-05-24 | Shanghai Kexin Biotech Co., Ltd. | Diagnostic and therapeutic uses of moesin fragments |
JP6080763B2 (ja) | 2010-10-08 | 2017-02-15 | シャンハイ クーシン バイオテック カンパニー,リミテッド | モエシンモジュレーターおよびその使用 |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
CN102875683B (zh) * | 2011-07-11 | 2014-06-11 | 旭华(上海)生物研发中心有限公司 | 长效重组人生长激素的Fc融合蛋白 |
EP2773662A4 (de) | 2011-10-31 | 2015-07-01 | Hoffmann La Roche | Antikörperformulierungen |
WO2013096516A1 (en) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Methods for treating acne |
JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
CN105377355A (zh) | 2013-03-14 | 2016-03-02 | 拇趾公司 | 治疗甲单元的感染、疾病或病症的方法 |
US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
CN111518199A (zh) | 2013-07-18 | 2020-08-11 | 图鲁斯生物科学有限责任公司 | 具有超长互补决定区的人源化抗体 |
CN105792851B (zh) | 2013-09-13 | 2023-10-10 | 斯克利普斯研究所 | 修饰的治疗剂及其组合物 |
WO2015057852A1 (en) | 2013-10-15 | 2015-04-23 | The California Institute For Biomedical Research | Chimeric antigen receptor t cell switches and uses thereof |
ES2845924T3 (es) | 2013-10-15 | 2021-07-28 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos |
CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
CN104623639A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | 白介素22二聚体在制备治疗胰腺炎药物中的应用 |
JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
CN106456589B (zh) | 2013-12-18 | 2020-07-07 | 斯克利普斯研究所 | 修饰的治疗剂、订合的肽脂质缀合物及其组合物 |
NL2014230B1 (en) | 2015-02-04 | 2016-10-12 | Stichting Vu-Vumc | Wound healing formulation. |
MA41629A (fr) | 2015-03-04 | 2018-01-09 | Center For Human Reproduction | Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité |
WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
US20190000928A1 (en) | 2015-06-17 | 2019-01-03 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
WO2018075807A1 (en) | 2016-10-19 | 2018-04-26 | California Institute For Biomedical Research | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
AR118536A1 (es) | 2019-04-01 | 2021-10-20 | Genentech Inc | Composiciones y métodos para estabilizar formulaciones que contienen proteína |
CA3149494A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
WO2021081440A2 (en) | 2019-10-24 | 2021-04-29 | Minotaur Therapeutics, Inc. | Chimeric cytokine modified antibodies and methods of use thereof |
JP2024517759A (ja) | 2021-04-28 | 2024-04-23 | ミノトール セラピューティクス インコーポレイテッド | ヒト化キメラウシ抗体および使用方法 |
WO2022233989A1 (en) | 2021-05-06 | 2022-11-10 | Hoba Therapeutics Aps | Prevention and treatment of chemotherapy-induced neuropathic pain |
WO2023104960A1 (en) | 2021-12-10 | 2023-06-15 | Hoba Therapeutics Aps | Treatment of nociceptive pain |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
DK0674506T3 (da) * | 1992-12-02 | 2001-01-08 | Alkermes Inc | Væksthormonholdige mikrosfærer med styret frigivelse |
ATE197398T1 (de) * | 1994-09-09 | 2000-11-11 | Takeda Chemical Industries Ltd | Zubereitung mit verzögerter freigabe eines metallsalz eines peptids |
-
1996
- 1996-06-03 PL PL96323832A patent/PL184531B1/pl not_active IP Right Cessation
- 1996-06-03 CA CA002223436A patent/CA2223436A1/en not_active Abandoned
- 1996-06-03 DK DK96919016T patent/DK0831787T3/da active
- 1996-06-03 EP EP96919016A patent/EP0831787B1/de not_active Expired - Lifetime
- 1996-06-03 CZ CZ19973907A patent/CZ288147B6/cs not_active IP Right Cessation
- 1996-06-03 ES ES96919016T patent/ES2161366T3/es not_active Expired - Lifetime
- 1996-06-03 BR BR9608542-8A patent/BR9608542A/pt not_active Application Discontinuation
- 1996-06-03 RU RU97119935/14A patent/RU2161502C2/ru not_active IP Right Cessation
- 1996-06-03 CN CN96194614A patent/CN1102854C/zh not_active Expired - Fee Related
- 1996-06-03 AU AU61469/96A patent/AU708756B2/en not_active Ceased
- 1996-06-03 JP JP9500870A patent/JPH11506740A/ja active Pending
- 1996-06-03 DE DE69614685T patent/DE69614685T2/de not_active Expired - Fee Related
- 1996-06-03 HU HU9900870A patent/HUP9900870A3/hu unknown
- 1996-06-03 IL IL12238596A patent/IL122385A/xx not_active IP Right Cessation
- 1996-06-03 WO PCT/US1996/008086 patent/WO1996040072A2/en not_active Application Discontinuation
- 1996-06-03 PT PT96919016T patent/PT831787E/pt unknown
- 1996-06-03 AT AT96919016T patent/ATE204468T1/de not_active IP Right Cessation
- 1996-06-03 SK SK1671-97A patent/SK281571B6/sk unknown
- 1996-06-03 NZ NZ310644A patent/NZ310644A/xx unknown
-
1997
- 1997-12-05 MX MX9709698A patent/MX9709698A/es not_active IP Right Cessation
- 1997-12-05 NO NO19975708A patent/NO316104B1/no unknown
-
1998
- 1998-08-19 HK HK98110029A patent/HK1009089A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX9709698A (es) | 1998-07-31 |
WO1996040072A3 (en) | 1997-01-23 |
CZ288147B6 (en) | 2001-05-16 |
EP0831787B1 (de) | 2001-08-22 |
HUP9900870A2 (hu) | 1999-09-28 |
ES2161366T3 (es) | 2001-12-01 |
PL323832A1 (en) | 1998-04-27 |
NZ310644A (en) | 1999-08-30 |
SK281571B6 (sk) | 2001-05-10 |
IL122385A0 (en) | 1998-06-15 |
PT831787E (pt) | 2002-02-28 |
HK1009089A1 (en) | 1999-09-10 |
DK0831787T3 (da) | 2001-12-17 |
CN1102854C (zh) | 2003-03-12 |
NO975708D0 (no) | 1997-12-05 |
NO975708L (no) | 1998-02-05 |
WO1996040072A2 (en) | 1996-12-19 |
BR9608542A (pt) | 1999-11-30 |
DE69614685D1 (de) | 2001-09-27 |
AU708756B2 (en) | 1999-08-12 |
HUP9900870A3 (en) | 2001-04-28 |
JPH11506740A (ja) | 1999-06-15 |
CN1187120A (zh) | 1998-07-08 |
SK167197A3 (en) | 1998-06-03 |
DE69614685T2 (de) | 2002-06-27 |
CZ390797A3 (cs) | 1998-07-15 |
EP0831787A2 (de) | 1998-04-01 |
IL122385A (en) | 2001-01-11 |
RU2161502C2 (ru) | 2001-01-10 |
AU6146996A (en) | 1996-12-30 |
PL184531B1 (pl) | 2002-11-29 |
CA2223436A1 (en) | 1996-12-19 |
NO316104B1 (no) | 2003-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69614685D1 (de) | Mittel zur verzögerten freisetzung von menschlichem wachstumshormon | |
MX9709699A (es) | Composicion para la liberacion sostenida de eritropoyetina no agregada. | |
CA2474698A1 (en) | Polymer-based compositions for sustained release | |
ATE228832T1 (de) | System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung | |
WO2001043749A3 (en) | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration | |
DE69840495D1 (de) | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben | |
WO2001058474A3 (en) | Microencapsulation and sustained release of biologically active agent | |
JPH07187994A (ja) | 薬物放出制御製剤 | |
EP1570823A3 (de) | Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin | |
ATE433318T1 (de) | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten | |
IS4083A (is) | Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja | |
UA29563C2 (uk) | Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду | |
ATE315409T1 (de) | Verbesserte formulierung zur gesteuerten arzneistofffreisetzung durch kombination hydrophiler und hydrophober stoffe | |
DE59908745D1 (de) | Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung | |
DE3850823D1 (de) | System zur Freisetzung von Medikamenten und dessen Herstellungsmethode. | |
AU7004194A (en) | Drug system | |
SK138096A3 (en) | Collagen preparation for the controlled release of active substances | |
ATE282406T1 (de) | Arzneimittel und verfahren zur behandlung von intrazellulären infektionen | |
WO2020166820A1 (ko) | 피나스테라이드를 포함하는 마이크로 입자를 함유한 피하 주사용 조성물 | |
WO2000025762A1 (de) | Vorrichtung für eine transdermale und phonophoretische kombinationsbehandlung und ihre verwendung in einem verfahren zur medizinischen anwendung | |
RU97115937A (ru) | Применение изосорбид-5-мононитрата |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |